Alitair Pharmaceuticals Announces Filing of Patent for Prescription Drug Overdose Reduction Technology

MORRISTOWN, New Jersey – Jan. 10, 2011 – Alitair Pharmaceuticals, Inc., a life sciences product development company, today announced that it has filed a patent application with the United States Patent & Trademark Office. The patent claims compositions and methods for reducing or eliminating the chance of overdosing on a prescription drug.

Alitair was earlier awarded a grant under the Qualifying Therapeutic Discovery Program (QTDP) to study methods for reducing drug overdose. The QTDP was part of the Health Care Reform Act and provides $1 billion in funding for projects that address an unmet medical need or would advance the effort toward a cure for cancer. Further, the product must lead to high quality manufacturing jobs in the United States. Alitair was awarded $244,479 for work to reduce the chance of accidental prescription drug overdose.

"We are extremely pleased to announce that Alitair has filed this important patent which will significantly further our work to reduce prescription drug overdose," said Dr. William Howard, President and CEO of Alitair Pharmaceuticals, Inc.

"Prescription drug overdose is a serious public health problem for which no technologies have been deployed to reduce the risk of prescription drug overdose," Dr. Howard continued. "According to the CDC, each year about 1 million patients go to the emergency room for prescription drug overdose, and about 150,000 are admitted to the hospital. About 14,000 of these patients die each year. CDC data show that the total number of deaths from cocaine and heroin overdose is about 5,000 and 2,000 per year respectively, so prescription drug overdose claims almost twice as many lives as cocaine and heroin combined. We believe there is a significant need for a technology that can reduce these overdose deaths."

About Alitair Pharmaceuticals:
Alitair Pharmaceuticals is a specialty pharmaceutical company focused on the development of new and improved respiratory, pain, and women’s health products. The Company is currently focused on prescription and OTC cough medications, but overdose reduction is an important area of long term research for Alitair.


Source: Alitair Pharmaceuticals, Inc.

Contact: Faith Pomeroy-Ward
Vice President, Corporate Development
817-490-5152 | This email address is being protected from spambots. You need JavaScript enabled to view it.